XML 33 R16.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Note 9 - Financial Instruments With Off-balance-sheet Risk | 12 Months Ended
--- | ---
Dec. 31, 2023
Notes to Financial Statements |
Financial Instruments Disclosure [Text Block] | Note 9. Financial instruments with off-balance-sheet risk In the normal course of business, the Company is party to financial instruments with off-balance-sheet risk to meet the financing needs of its borrowers. These financial instruments include commitments to extend credit and involve, to varying degrees, elements of credit risk in excess of the amount recognized in the consolidated statement of assets and liabilities. The Company attempts to limit its credit risk by conducting extensive due diligence and obtaining collateral where appropriate. The balance of unfunded commitments to extend credit was $180.5 million and $190.0 million as of December 31, 2023 and 2022, respectively. Commitments to extend credit consist principally of the unused portions of commitments that obligate the Company to extend credit, often subject to financial or non-financial milestones and other conditions to borrow that must be achieved before the commitment can be drawn. In addition, the commitments generally have fixed expiration dates or other termination clauses. Since commitments may expire without being drawn upon, the total commitment amounts do not necessarily represent future cash requirements. The following table provides the Company’s unfunded commitments by portfolio company as of December 31, 2023 and 2022:
|  | December 31, 2023 |  |  | December 31, 2022 |
|  |  |  |  |  | Fair Value of |  |  |  |  |  |  | Fair Value of |
|  |  |  |  |  | Unfunded |  |  |  |  |  |  | Unfunded |
|  | Principal |  |  | Commitment |  |  | Principal |  |  | Commitment |
|  | Balance |  |  | Liability |  |  | Balance |  |  | Liability |
|  | (In thousands) |  |  | (In thousands) |
BrightInsight, Inc. |  | $ | 15,500 |  |  | $ | 241 |  |  | $ | 21,000 |  |  | $ | 278 |
Britecore Holdings, Inc. |  |  | 5,000 |  |  |  | 72 |  |  |  | 5,000 |  |  |  | 66 |
Candesant Biomedical Corporation |  |  | 10,000 |  |  |  | 151 |  |  |  | — |  |  |  | — |
Castle Creek Biosciences |  |  | — |  |  |  | — |  |  |  | 4,000 |  |  |  | 72 |
Divergent Technologies, Inc. |  |  | 11,250 |  |  |  | 118 |  |  |  | 22,500 |  |  |  | 236 |
Elligo Healthcare Research, Inc. |  |  | 15,000 |  |  |  | 194 |  |  |  | — |  |  |  | — |
Engage3, LLC |  |  | — |  |  |  | — |  |  |  | 8,000 |  |  |  | 40 |
Groundspeed Analytics, Inc. |  |  | — |  |  |  | — |  |  |  | 15,000 |  |  |  | 150 |
Hound Labs, Inc. |  |  | — |  |  |  | — |  |  |  | 7,500 |  |  |  | 88 |
KSQ Therapeutics, Inc. |  |  | — |  |  |  | — |  |  |  | 10,000 |  |  |  | 100 |
Lytics, Inc. |  |  | — |  |  |  | — |  |  |  | 5,000 |  |  |  | 65 |
MicroTransponder, Inc. |  |  | 22,500 |  |  |  | — |  |  |  | — |  |  |  | — |
Mirantis, Inc. |  |  | 15,000 |  |  |  | 136 |  |  |  | — |  |  |  | — |
Native Microbials, Inc. |  |  | — |  |  |  | — |  |  |  | 7,500 |  |  |  | 72 |
Optoro, Inc. |  |  | 6,250 |  |  |  | — |  |  |  | 15,000 |  |  |  | 38 |
Parse Biosciences, Inc. |  |  | 15,000 |  |  |  | 251 |  |  |  | — |  |  |  | — |
PDS Biotechnology Corporation |  |  | — |  |  |  | — |  |  |  | 10,000 |  |  |  | 158 |
Robin Healthcare, Inc. |  |  | — |  |  |  | — |  |  |  | 10,000 |  |  |  | 100 |
SafelyYou, Inc. |  |  | 20,000 |  |  |  | 270 |  |  |  | — |  |  |  | — |
Scientia Vascular, Inc. |  |  | — |  |  |  | — |  |  |  | 10,000 |  |  |  | 110 |
Slingshot Aerospace, Inc. |  |  | — |  |  |  | — |  |  |  | 5,000 |  |  |  | 64 |
Sonex Health, Inc. |  |  | 15,000 |  |  |  | 176 |  |  |  | — |  |  |  | — |
Supply Network Visibility Holdings, LLC |  |  | 10,000 |  |  |  | 35 |  |  |  | — |  |  |  | — |
Swift Health Systems Inc. |  |  | — |  |  |  | — |  |  |  | 25,500 |  |  |  | 105 |
Tallac Therapeutics, Inc. |  |  | 10,000 |  |  |  | 229 |  |  |  | — |  |  |  | — |
Temperpack Technologies, Inc. |  |  | — |  |  |  | — |  |  |  | 9,000 |  |  |  | 19 |
Viken Detection Corporation |  |  | 10,000 |  |  |  | 160 |  |  |  | — |  |  |  | — |
Total |  | $ | 180,500 |  |  | $ | 2,033 |  |  | $ | 190,000 |  |  | $ | 1,761 |
The table above also provides the fair value of the Company’s unfunded commitment liability as of December 31, 2023 and 2022 which totaled $2.0 million and $1.8 million, respectively. The fair value at inception of the delay draw credit agreements is equal to the fees and/or warrants received to enter into these agreements, taking into account the remaining terms of the agreements and the counterparties’ credit profile. The unfunded commitment liability reflects the fair value of these future funding commitments and is included in the Company’s consolidated statement of assets and liabilities.

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures. + References No definition available. + Details
Name: | us-gaap_FinancialInstrumentsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration